Skip to main content
. 2022 Jan 14;12:796046. doi: 10.3389/fneur.2021.796046

Table 2.

Characteristics of minor ischemic stroke patients presenting with (n = 23) or without large vessel occlusion (LVO; n = 557).

Patients without LVO (N = 559) Patients with LVO (N = 23) P Value
Age mean ± SD, y 73.4 ± 16.3 70.1 ± 17.8 0.287
Age median (IQR), y 78 (64–86) 72 (5–84)
Male, n (%) 277 (49.6) 12 (52.2) 0.805
Hypertension, n (%) 389 (69.6) 14 (60.9) 0.375
Diabetes mellitus, n (%) 115 (20.6) 3 (13.0) 0.377
Hypercholesterolemia, n (%) 208 (37.4) 4 (17.4) 0.051
Current smoking, n (%) 0.361
   Yes 85 (15.3) 3 (12.0)
   No 430 (76.8) 19 (84.0)
   Unknown 44 (7.9) 1 (4.0)
History of AF, n (%) 119 (21.4) 10 (43.5) 0.012
Current alcohol consumption, n (%) 33 (6.3) 0 (0.0) 0.226
Coronary heart disease, n (%) 72 (13.0) 3 (13.0) 0.997
Chronic heart failure, n (%) 40 (7.3) 0 (0.0) 0.179
Peripheral artery disease, n (%) 39 (7.0) 1 (4.4) 0.618
Active cancer, n (%) 18 (3.3) 2 (8.7) 0.168
Previous TIA, n (%) 80 (14.3) 5 (21.7) 0.323
Previous stroke, n (%) 111 (19.9) 6 (27.3) 0.395
Prestroke treatments, n (%)
Antiplatelets agents 185 (33.3) 8 (34.8) 0.885
Anticoagulants 84 (15.1) 3 (13.0) 0.783
Antihypertensive treatment 353 (63.6) 12 (52.2) 0.266
Statins 142 (25.6) 2 (8.7) 0.066
NIHSS score at onset, median (IQR) 2 (1–3) 3 (2–5) 0.001
Prestroke cognitive status, n (%) 0.567
No cognitive impairment 448 (80.3) 19 (82.6)
MCI 58 (10.4) 1 (4.4)
Dementia 52 (9.3) 3 (13.0)
Premorbid mRS score>2, n (%) 117 (20.9) 5 (21.7) 0.926
Living in an institution, n (%) 41 (7.4) 0 (0.0) 0.177
TOAST classification, n (%) 0.011
LAA 60 (10.7) 1 (4.4)
CE 130 (23.3) 13 (56.5)
SVD 52 (9.3) 0 (0.0)
Other 42 (7.5) 1 (4.4)
Undetermined 247 (44.2) 8 (34.8)
Multiple causes 28 (5.0) 0 (0.0)

AF, indicates atrial fibrillation; CE, cardioembolic; IQR, interquartile range; IV, intravenous; LAA, large artery atheroma; MCI, mild cognitive impairment; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SVD, Small Vessel Disease; TIA, Transient Ischemic Attack; and TOAST, Trial of ORG 10172 in Acute Stroke Treatment.